Recursion Pharmaceuticals (RXRX) Depreciation and Depletion (2020 - 2024)

Recursion Pharmaceuticals has reported Depreciation and Depletion for 5 years, with the latest figure at $6.2 million in Q4 2024.

• For the quarter ending Q4 2024, Depreciation and Depletion rose 47.62% year-over-year to $6.2 million; the trailing twelve-month figure through Dec 2024 stood at $18.3 million (up 14.38% YoY), and the FY2025 full-year result was $33.7 million, up 84.15% from the prior year.
• Depreciation and Depletion for Q4 2024 stood at $6.2 million, up from $4.0 million in the prior quarter.
• The five-year high for Depreciation and Depletion was $6.2 million in Q4 2024, with the low at $1.0 million in Q1 2020.
• Historically, Depreciation and Depletion has averaged $2.9 million across 5 years, with a median of $2.8 million in 2022.
• Annual changes were most pronounced in 2021 — Depreciation and Depletion jumped 140.0% — and 2024, when it fell 4.76%.
• Recursion Pharmaceuticals' Depreciation and Depletion stood at $1.1 million in 2020, then surged by 127.27% to $2.5 million in 2021, then grew by 24.0% to $3.1 million in 2022, then soared by 35.48% to $4.2 million in 2023, then surged by 47.62% to $6.2 million in 2024.
• The last three Depreciation and Depletion figures came in at $6.2 million (Q4 2024), $4.0 million (Q3 2024), and $4.1 million (Q2 2024), per Business Quant data.